Dr. Mark Demesmaeker

Angestellt, Head of Digital Strategy and Product Portfolio, Cytiva (formerly GE Life Sciences)

Genf, Schweiz

Fähigkeiten und Kenntnisse

PhD-level Life Science professional and business l
Passionate about Analytics challenges in Pharmaceu
Strategie
Arzneimittel
IBM

Werdegang

Berufserfahrung von Mark Demesmaeker

  • Bis heute 1 Jahr und 8 Monate, seit Nov. 2022

    Head of Digital Strategy and Product Portfolio

    Cytiva (formerly GE Life Sciences)

    At Cytiva my role is to create and continuosly evolve Cytiva's portfolio of advanced digital products and services - pushing the boundaries of digital process development and Biomanufacturing of life saving drugs and vacines.

  • 4 Jahre und 6 Monate, Juni 2018 - Nov. 2022

    Head of Data Analytics

    Sartorius Stedim Biotech

  • 2 Jahre und 7 Monate, Dez. 2015 - Juni 2018

    Vice President, Translational & Clinical Analytics

    PerkinElmer Inc.

    At PerkinElmer Informatics I am responsible for developing and implementing the global analytics product strategy and services portfolio to drive analytics across healthcare, life and physical sciences markets. My role includes defining the go-to-market strategy, development of external collaborations (including potential partnership and strategic acquisitions), as well as thought leader relationships to manage and effect technology assessment and platform development.

  • 7 Monate, Mai 2015 - Nov. 2015

    Associate Partner, Leader Life Science Analytics

    IBM Switzerland Ltd

    At IBM my role was to lead Life Science Analytics within the central EMEA region, shaping the delivery team and go to-market strategy around eHealth and Real-World Evidence in close cooperation with the IBM Watson Health Unit.

  • 1 Jahr und 4 Monate, Jan. 2014 - Apr. 2015

    Managing Director, EMEA & Asia Operations

    Integrated Clinical Systems Inc.

    I am currently managing EMEA & Asia Operations of Integrated Clinical Systems Inc. ICS has developed JReview®, the most comprehensive clinical review and -analysis software tool in the market. It provides an intuitive user interface to perform the tasks required to conduct safety and efficacy review, as well as risk-based monitoring activities through clinically relevant reports and interactive data visualizations.

  • 1 Jahr und 5 Monate, Sep. 2012 - Jan. 2014

    Director, Industry Analytics

    Tibco Software AG

    - Practice lead in advanced analytics - injecting subject matter expertise to all phases of the sales and delivery cycle. Define innovative and predictive analytic applications solving business-critical issues in the Life Sciences, Energy, Financial Services, Consumer Goods & Retail (CPR) and Telco, Media & Networks industries. - EU Press- and Analyst spokesperson for TIBCO Spotfire

  • 11 Jahre und 5 Monate, Apr. 2001 - Aug. 2012

    European Manager, Solutions Consulting

    Tibco Software AG

    - Manage/grow TIBCO Spotfire’s EMEA solutions consulting organization - covering various markets, such as pharmaceuticals/life sciences, financial services, energy, high-tech manufacturing, and telecommunications. - Manage business analytics consulting engagements with numerous global Pharmaceutical- and Biotech corporations, aimed at optimizing business analytics processes as well as the performance of R&D-, and sales & marketing organizations. - Technical/scientific field marketing - EU Press- and A

  • 1 Jahr und 4 Monate, Jan. 2000 - Apr. 2001

    Scientific Consultant

    Spotfire, Inc.

    - Global pre-sales consulting with Spotfire’s strategic life science customers, positioning and designing data analytics workflows across all verticals within pharmaceutical R&D (genomics, proteomics, screening, medicinal chemistry, pre-clinical-, and clinical development (phases I-IV)). - Speaker at multiple international scientific congresses and seminars. - Development of Spotfire product- and market strategies for life science R&D.

  • 2 Jahre und 7 Monate, Juni 1997 - Dez. 1999

    Technical Officer, Quality Assurance and Safety: Medicines

    World Health Organization, Geneva, Switzerland

    - International Pharmacopoeia - WHO expert committes on quality of pharmaceutical products - International Nonproprietary Names (INN) for pharmaceuticals - International Conference on Harmonization (ICH)

  • 4 Jahre und 8 Monate, Okt. 1992 - Mai 1997

    Reasearch Fellow, Post-doc

    Pharmazeutisches Institut, Universität Kiel, Germany

    - Teaching: Medicinal chemistry & pharmacology; Lab research in drug metabolism & carcinogenesis

Ausbildung von Mark Demesmaeker

  • 2007 - 2008

    Business & Administration

    IMD Business School, Lausanne, Switzerland

  • 1992 - 1997

    Pharmacokinetics

    Christian Albrechts Universität Kiel, Germany

    Ph.D. Thesis in Pharmacokinetics/Drug Metabolism & Medicinal Chemistry - Postdoc

  • 1988 - 1991

    Pharmaceutical Sciences

    Rheinische Friedrich-Wilhelms-Universität Bonn, Germany

Sprachen

  • Deutsch

    -

  • Englisch

    -

  • Spanisch

    -

  • Französisch

    -

Interessen

Analytics
Business Intelligence
Translational Medicine
Clinical/pre-clinical Pharmacology
Clinical Safety
Clinical Trial Operations
Pharmacovigilance
Risk-based Monitoring
Trial enrolment prediction
Predictive modeling
Health economics and outcomes research
Sales force effectiveness
Market research
Business Development
and above all Cycling!

21 Mio. XING Mitglieder, von A bis Z